【辉瑞靶向治疗创新药泰泽纳®在华获批】金十数据11月5日讯,辉瑞公司宣布,其治疗前列腺癌的创新药泰泽纳®(TALZENNA®,通用名:甲苯磺酸他拉唑帕利胶囊)于2024年10月29日获得国家药品监督管理局(NMPA)批准,联合恩扎卢胺用于HRR基因突变的转移性去势抵抗性前列腺癌 (mCRPC) 成人患者,成为中国目前唯一获批HRR基因突变的mCRPC治疗的PARP抑制剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.